1. Home
  2. KTTA vs VRAX Comparison

KTTA vs VRAX Comparison

Compare KTTA & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KTTA
  • VRAX
  • Stock Information
  • Founded
  • KTTA 2020
  • VRAX 2013
  • Country
  • KTTA United States
  • VRAX United Kingdom
  • Employees
  • KTTA N/A
  • VRAX N/A
  • Industry
  • KTTA Biotechnology: Pharmaceutical Preparations
  • VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • KTTA Health Care
  • VRAX Health Care
  • Exchange
  • KTTA Nasdaq
  • VRAX Nasdaq
  • Market Cap
  • KTTA 5.5M
  • VRAX 4.7M
  • IPO Year
  • KTTA 2021
  • VRAX 2022
  • Fundamental
  • Price
  • KTTA $0.68
  • VRAX $0.91
  • Analyst Decision
  • KTTA
  • VRAX Strong Buy
  • Analyst Count
  • KTTA 0
  • VRAX 1
  • Target Price
  • KTTA N/A
  • VRAX $3.00
  • AVG Volume (30 Days)
  • KTTA 142.8K
  • VRAX 55.7K
  • Earning Date
  • KTTA 08-12-2025
  • VRAX 02-05-2025
  • Dividend Yield
  • KTTA N/A
  • VRAX N/A
  • EPS Growth
  • KTTA N/A
  • VRAX N/A
  • EPS
  • KTTA N/A
  • VRAX N/A
  • Revenue
  • KTTA N/A
  • VRAX $6,331.00
  • Revenue This Year
  • KTTA N/A
  • VRAX $217,274.83
  • Revenue Next Year
  • KTTA N/A
  • VRAX N/A
  • P/E Ratio
  • KTTA N/A
  • VRAX N/A
  • Revenue Growth
  • KTTA N/A
  • VRAX N/A
  • 52 Week Low
  • KTTA $0.67
  • VRAX $0.74
  • 52 Week High
  • KTTA $7.50
  • VRAX $9.00
  • Technical
  • Relative Strength Index (RSI)
  • KTTA 32.67
  • VRAX 50.78
  • Support Level
  • KTTA $0.67
  • VRAX $0.84
  • Resistance Level
  • KTTA $0.77
  • VRAX $0.99
  • Average True Range (ATR)
  • KTTA 0.04
  • VRAX 0.07
  • MACD
  • KTTA 0.01
  • VRAX 0.02
  • Stochastic Oscillator
  • KTTA 14.02
  • VRAX 60.20

About KTTA Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

Share on Social Networks: